BioXcel Therapeutics (BTAI) Misses Q1 EPS by 22c

BioXcel Therapeutics (NASDAQ: BTAI) reported Q1 EPS of ($1.84), $0.22 worse than the analyst estimate of ($1.62). Revenue for the quarter came in at $210 thousand versus the consensus estimate of $447.1 thousand.

For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• BMO starts chip stocks coverage: Here are its preferred picks
• Intchains Group Ltd (ICG) PT Lowered to $2 at Benchmark Following 1H Results